

# **1 Differential expression analyses on aortic tissue reveal novel genes and pathways associated 2 with abdominal aortic aneurysm onset and progression**

3 Gerard Temprano-Sagrera MSc (gtemprano@santpau.cat)<sup>1</sup>, Begoña Soto MD PhD  
4 (bsoto@santpau.cat)<sup>1,2</sup>, Jaume Dilmé MD PhD (jdilme@santpau.cat)<sup>1,2,3</sup>, Olga Peypoch MD  
5 (opeypoch@santpau.cat)<sup>1,2</sup>, Laura Calsina Juscafresa MD PhD (lcalsina@psmar.cat)<sup>4,5</sup>, David  
6 Davtian PhD<sup>6</sup> (2400580@dundee.ac.uk), Lluís Nieto MD (lnietofernandez@gmail.com)<sup>4</sup>,  
7 Andrew Brown PhD (a.z.t.brown@dundee.ac.uk)<sup>6</sup>, José Román Escudero MD  
8 (jescudero@santpau.cat)<sup>1,2</sup>, Ana Viñuela PhD# (ana.vinuela@newcastle.ac.uk)<sup>7</sup>, Mercedes  
9 Camacho PhD# (mcamacho@santpau.cat)<sup>1</sup>, Maria Sabater-Lleal PhD#  
10 (msabater@santpau.cat)<sup>1,8,9</sup>

11

12 #These authors equally contributed as senior authors.

13

14 Affiliations:

15

- 16 1. Unit of genomics of Complex Diseases, Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79,  
17 08041 Barcelona, Spain
- 18 2. Servei d'Angiologia i Cirurgia Vascular i Endovascular, Hospital de la Santa Creu i Sant Pau, Sant Antoni  
19 Maria Claret 167, 08025 Barcelona, Spain
- 20 3. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERECV), Madrid,  
21 Spain
- 22 4. Department of Vascular and Endovascular Surgery, Hospital del Mar, Passeig Marítim 25-29, 08003,  
23 Barcelona, Spain
- 24 5. Department of Medicine and Surgery, Universitat Pompeu Fabra, Barcelona, Spain
- 25 6. Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee,  
26 Dundee, DD1 9SY, United Kingdom.
- 27 7. Biosciences Institute, Faculty of Medical Sciences, University of Newcastle, Newcastle upon Tyne, NE1  
28 4EP, United Kingdom
- 29 8. Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
- 30 9. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain

31

32

33 Corresponding author:

34

35 Maria Sabater-Lleal, PhD  
36 Genomics of Complex Disease Unit, Institut de Recerca Sant Pau (IR SANT PAU)  
37 St Quintí 77-79, 08041, Barcelona, Spain  
38 Phone +34932919000; Email: msabater@santpau.cat

39

## 40 ABSTRACT

### 41 Background:

42 Abdominal aortic aneurysms (AAA) are focal dilatations of the abdominal aorta. They are  
 43 normally asymptomatic and progressively expand, increasing their risk of rupture. Rupture of  
 44 an AAA is associated with high mortality rates, but the mechanisms underlying the initiation,  
 45 expansion and rupture of AAA are not yet fully understood. This study aims to characterize and  
 46 identify new genes associated with the pathophysiology of AAA through differential expression  
 47 analyses between dilated and non-dilated aortic tissue samples, and between AAA of different  
 48 diameters. Our study used RNA-seq data on 140 samples, becoming the largest RNA-seq  
 49 dataset for differential expression studies of AAA.

### 50 Results:

51 We identified 7,454 differentially expressed genes (DEGs) between AAA and controls, 2,851 of  
 52 which were new compared to previous microarray studies. Notably, a novel cluster on  
 53 adenosine triphosphate synthesis regulation emerged as strongly associated with AAA.  
 54 Additionally, exploring AAA of different diameters identified eight genes (*EXTL3*, *ZFR*, *DUSP8*,  
 55 *DISP1*, *USP33*, *VPS37C*, *ZNF784*, *RFX1*) that overlapped with the DEGs between AAA and  
 56 controls, implying roles in both disease onset and progression. Seven genes (*SPP1*, *FHL1*, *GNAS*,  
 57 *MORF4L2*, *HMG1*, *ARL1*, *RNASE4*) with differential splicing patterns were also DEGs between  
 58 AAA and controls, suggesting that splicing differences contribute to the observed expression  
 59 changes and the disease development.

### 60 Conclusions:

61 This study identified new genes and pathways associated with AAA onset and progression and  
 62 validated previous relevant roles of inflammation and intracellular calcium regulation. These

63 findings provide insights into the complex mechanisms underlying AAA and indicate potential  
64 targets to limit AAA progression and mortality risk.

65 **KEYWORDS:** Abdominal aortic aneurysm, RNAseq, transcriptomics, differential expression,  
66 ischemic time, alternative splicing, allelic specific expression.

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

## 84 BACKGROUND:

85 Abdominal aortic aneurysms (AAA) are characterized by a local dilation of the infrarenal  
86 abdominal aorta to about 1.5 times the normal adjacent aortic diameter or more than 3 cm in  
87 maximum diameter[1]. AAA is accompanied by chronic inflammation, apoptosis of vascular  
88 smooth muscle cells and neovascularization[2,3]. Additionally, extracellular matrix degradation,  
89 microcalcification, and oxidative stress contribute to the degeneration of the aorta[1,2]. The  
90 disease is progressive, and most aneurysms develop without causing symptoms[1]. However, in  
91 the event of AAA rupture, mortality rates can reach 80 %[4]. The only effective treatment  
92 currently available for AAA is aortic tissue repair, either through open surgery or endovascular  
93 repair[1,5].

94 Some risk factors are known for developing AAA, including age, male sex, smoking, and family  
95 history of AAA[1]. Smoking, in addition, is also known to increase the risk of rupture[6].  
96 Additionally, recent genomic studies have revealed 121 loci associated with risk of developing  
97 AAA, contributing to the knowledge of the possible pathways leading to this disease[7].  
98 However, there is still an insufficient understanding of the clear mechanisms that underlie the  
99 initiation, propagation, and rupture of AAA.

100 The study of gene expression, known as transcriptomics, is a valuable tool for understanding  
101 human disease and revealing new therapeutic targets [8,9]. Several studies have been  
102 performed to study the differentially expressed genes (DEGs) between dilated aortic tissue and  
103 non-dilated control aorta using microarray technology, detecting DEGs especially associated  
104 with the immune and inflammatory responses, extracellular matrix remodeling and  
105 angiogenesis[10–15]. In the present study, we performed RNA sequencing (RNAseq) of the  
106 complete transcriptome in 140 abdominal aortic tissue samples (96 dilated aortas and 44  
107 control aortas from deceased donors) from the Triple A Barcelona Study (TABS) cohort, to  
108 identify new DEGs and pathways associated with the pathophysiology of AAA initiation and

109 progression, allowing for a more comprehensive analysis of the transcriptome and becoming  
110 the largest RNAseq dataset for AAA tissue. Additionally, we aimed to investigate the differences  
111 in alternative splicing patterns in the context of AAA, and the role of genetic variants in gene  
112 expression in AAA tissue. The study design is described in **Figure 1**.

## 113 RESULTS:

### 114 Participants characteristics:

115 **Table 1** shows the participants demographic and clinical data. Aortic tissue samples from 96  
116 AAA patients and 44 controls from the TABS cohort were used for RNAseq analysis.

**Table 1: Characteristics of study participants**

	<b>Controls (N = 44)</b>	<b>AAA (N = 96)</b>	<b>P-value</b>	<b>Missing values (%)</b>
<b>Age (Years)</b>	61.66 (21-82)	70.38 (53-87)	0.0006	0 (0)
<b>Sex (Male)</b>	21 (47.73)	92 (95.83)	1.00E-10	0 (0)
<b>Smoking (Current)</b>	8 (21.62)	27 (32.14)	0.3378	19 (13.57)
<b>Smoking (Past)</b>	3 (8.11)	42 (50)	2.81E-05	19 (13.57)
<b>Aortic Diameter (mm)</b>	NA	65.57 (38-100.12)	-	0 (0)
<b>Hypertension (Yes)</b>	15 (40.54)	54 (64.29)	0.0256	19 (13.57)
<b>Dyslipidemia (Yes)</b>	10 (27.03)	46 (54.76)	0.0087	19 (13.57)
<b>Diabetes mellitus (Yes)</b>	5 (13.51)	12 (14.29)	1	19 (13.57)
<b>Peripheral arterial disease (Yes)</b>	NA	23 (27.71)	-	57 (59.38)
<b>Other aneurysms (Yes)</b>	NA	25 (29.76)	-	12 (12.5)
<b>Cerebrovascular Disease (Yes)</b>	3 (8.11)	36 (43.9)	0.0003	21 (15)
<b>Cardiovascular Disease (Yes)</b>	1 (3.34)	16 (19.05)	0.0846	27 (19.29)
<b>Chronic obstructive pulmonary disease (Yes)</b>	1 (2.7)	15 (17.86)	0.0481	19 (13.57)

Chronic kidney disease (Yes)	2 (5.4)	17 (20.24)	0.0726	19 (13.57)
------------------------------	---------	------------	--------	------------

*Continuous variables are presented as mean (range), and categorical variables are presented as %. Two-sample t-tests and chi-squared tests were used to compare the means of continuous phenotypes and the distribution of categorical phenotypes, between AAA and control groups, respectively. Missing values were excluded from the calculations of each variable. Hypertension was defined based on clinical history and the use of antihypertensive medication. Dyslipidemia was diagnosed through clinical history and the use of hypolipidemic medication. Diabetes mellitus was identified by clinical history and the use of insulin or oral hypoglycemic medications, without differentiation between type 1 or type 2. Peripheral arterial disease was assessed based on clinical symptoms and clinical history. Other aneurysms included thoracic and visceral aortic aneurysms, iliac artery aneurysms, and popliteal artery aneurysms, and were diagnosed using computed tomography or ultrasound. Cerebrovascular diseases were determined by a history of transient ischemic attack or stroke. Cardiovascular diseases were assessed by history of acute myocardial infarction or angina pectoris, or admission with clinical symptoms, electrocardiogram changes, or a positive enzymatic curve diagnosed by a cardiologist. Chronic obstructive pulmonary disease was identified based on clinical history. Chronic kidney disease was assessed by clinical history.*

117 We examined demographic and clinical variables between AAA and controls to determine  
118 whether these might influence our expression levels differences. We found significant  
119 differences in sex (**Additional file 1: Figure S1A**), age (**Additional file 1: Figure S1B**), smoking  
120 status, and the prevalence of hypertension, dyslipidemia, cerebrovascular disease, and chronic  
121 obstructive pulmonary disease between AAA patients and controls. In relation to smoking  
122 status (N = 122), which is a known risk factor for AAA development and rupture, 70.3 % of  
123 controls were never smokers, compared to 17.86 % of AAA patients. Among current and past  
124 smokers, there were also differences, with 50 % of former smokers and 32.14 % of current  
125 smokers in AAA, compared to only 8.11 % and 21.62 % respectively, in the controls (**Additional**

126 **file 1: Figure S3C**). We adjusted our regression analyses for age and sex, acknowledging their  
127 potential influence on expression level differences.

#### 128 Differential expression analyses between AAA and controls:

129 The analysis of differential expression between aortic samples from 96 AAA patients and 44  
130 controls revealed 7,454 genes displaying significant differences in expression (adjusted p-value  
131  $< 0.05$ ) (**Additional file 1: Figure S2A and Additional file 2: Table S1**). This number exceeds by  
132 26.57 % the previous DEGs identified in comparable analyses using microarray  
133 technologies[10–15]. Using GO and KEGG enrichment analyses, we found a total of 1,152 and  
134 89 enriched terms, respectively (**Additional file 1: Figure S3A and Figure S4A**). The complete  
135 results of the enriched terms for GO and KEGG are shown in **Additional files 3 and 4: Tables S2**  
136 **and S3**. To better characterize the biological processes associated with the DEGs in the  
137 enrichment analysis, we performed a cluster analysis of GO pathways. We found that most of  
138 the DEGs were associated with the immune system: regulation of mononuclear cell  
139 proliferation, leukocyte chemotaxis, regulation of adaptive immune response based on somatic  
140 recombination of immune receptors built from immunoglobulin superfamily domains, mast cell  
141 degranulation, major histocompatibility complex (MHC) class II protein complex, positive  
142 regulation of T cell activation, and CD4-positive alpha-beta T cell differentiation (**Figure 2A**).  
143 Other represented metabolic pathways were related to sequestering of calcium ion, regulation  
144 of actin filament length and adenosine triphosphate (ATP) synthesis coupled electron transport  
145 (**Figure 2A**). While these analyses corroborated previous associations with inflammatory, actin  
146 filament regulation and intracellular calcium regulation processes, the ATP synthesis regulation  
147 pathway was a new differential expressed pathway in AAA tissue.

148 Control aortic samples from deceased organ donors have been used by us and others [10–  
149 13,15]. To account for differences in gene expression between AAA and control tissue that  
150 could be attributed to ischemic time (time between the donor's death and sample collection

151 when blood flow is interrupted), we removed 10,737 DEGs associated to ischemic time in the  
152 GTEx aorta samples (N = 387)[16] from the total DEGs found between AAA and controls,  
153 leaving 3,002 DEGs (**Additional file 1: Figure S2B and Additional file 5: Table S4**).

154 We then performed a new enrichment analysis and identified 424 enriched GO terms and 65  
155 KEGG pathways (**Additional file 1: Figure S3B and Figure S4B**) (Complete results are available  
156 at **Additional files 6 and 7: Tables S5 and S6**, respectively), which represented removal of 728  
157 and 24 pathways susceptible of being caused by ischemic time, respectively. Cluster analysis of  
158 GO enriched terms confirmed identified clusters related to the regulation of calcium ion  
159 retention, ATP synthesis coupled electron transport, and immune response centered on T cell  
160 activation (MHC class II protein complex, positive regulation of T cell activation). On the other  
161 hand, other clusters also associated with the immune system were no longer represented  
162 (regulation of mononuclear cell proliferation, leukocyte chemotaxis regulation of adaptive  
163 immune response based on somatic recombination of immune receptors built from  
164 immunoglobulin superfamily domains, CD4-positive, alpha-beta T cell differentiation, mast cell  
165 degranulation) together with the regulation of actin filament length (**Figure 2B**). By accounting  
166 for genes whose expression was altered by ischemic time, we identified a set of genes that are  
167 less likely to be affected by the experimental limitations of these types of studies.

168 Vascular inflammation has been previously associated to AAA development and  
169 progression[17,18]. Even in our most stringent analysis, which removed pathways possibly  
170 caused by ischemic time, there was a notable enrichment of pathways associated with the  
171 immune response. Consequently, we decided to investigate the influence of the inflammatory  
172 infiltrate on AAA by comparing the abundance of 22 immune cell types from gene expression  
173 profiles between our AAA and control samples. After correcting for multiple testing, we found  
174 significant differences on the abundances of CD8 T-cells, natural killer (NK) resting cells, and  
175 dendritic activated cells (**Figure 2C**). AAA samples had a higher proportion of CD8 T-cells, while



controls had more NK resting cells and dendritic activated cells. **Table 2** provides a summary of the three cell populations with the highest and lowest presence in each group. The findings support the previously reported involvement of CD8 T-cells and NK cells in AAA.[17,18] The lower levels of dendritic cells detected in AAA were unexpected, as previous studies found significantly higher levels of dendritic cells in AAA samples compared to controls[19].

**Table 2: Summary of the three most and least prevalent cell populations in AAA and controls.**

Cell Populations (AAA)	Percentage (%)	Cell Populations (Controls)	Percentage (%)
Plasma B cells	9.46	Resting mast cells	12.34
M2 macrophages	8.68	Resting memory CD4 T cells	8.31
Resting mast cells	6.99	M2 Macrophages	8.23
M1 macrophages	1.43	Eosinophils	2.03
Eosinophils	1.37	T cell follicular helper cells	1.94
Activated dendritic cells	1.13	M1 Macrophages	1.45

### Study of alternative splicing:

The relevance of alternative splicing in the development of diseases, such as cancer, neurological, and cardiovascular diseases has been well-established for years.[20] However, capturing the complexity of alternative splicing has been challenging. With the recent improvements in sequencing techniques it is now possible to study alternative splicing in more depth.[20] We investigated alternative splicing patterns between the AAA and control groups to identify specific splicing patterns associated with AAA. We identified 15 significant alternative splicing events on eleven unique genes (*FHL1*, *GNAS*, *ASAH1*, *SPP1*, *ARL1*, *MORF4L2*, *CYCS*, *HMGB1*, *HMG1*, *SELENOP*, *RNASE4*) between AAA and controls. The analysis revealed that, as anticipated, the number of altered alternative first exon events was more represented than any other splice event among AAA and control samples (**Figure 3A**), consistent with

194 previous work suggesting that it is the most frequent splice event in the human genome[21]  
 195 (Complete results are available in **Additional file 8: Table S7**). A functional enrichment analysis  
 196 was conducted on the eleven genes with significant alternative splicing events, but no  
 197 significantly enriched metabolic pathways were found. Interestingly, seven out of the eleven  
 198 genes were also differentially expressed between AAA and controls, suggesting that the  
 199 expression of specific splicing variants could be altered in AAA (**Figure 3B**).

#### 200 Differential expression analysis by aortic diameter:

201 The diameter of AAA is a significant risk factor for rupture. We analyzed the DEGs by diameter  
 202 to identify alterations in gene expression throughout the progression of the disease. We  
 203 observed a total of 32 DEGs among aneurysms of varying diameters (N = 84), although no  
 204 enriched pathways were identified (**Additional file 1: Figure S2C and Additional file 9: Table**  
 205 **S8**). Of the 32 DEGs by diameter, eight were also DEGs between AAA and controls (**Figure 3C**),  
 206 suggesting that these eight genes are relevant for disease formation and also during disease  
 207 progression.

#### 208 Allelic specific expression:

209 We investigated the potential effect of AAA-associated genetic variants on gene expression in  
 210 diseased tissue by studying allele specific expression in twelve AAA samples with available  
 211 genetic data. On average, we identified 529 genes with significant allele specific expression  
 212 (adjusted p-value < 0.05) in the twelve AAA samples. Among these genes, 90 exhibited  
 213 significant allele specific expression in more than five of the twelve AAA samples. Additionally,  
 214 to determine whether these associations were related to AAA or were characteristic of the  
 215 aortic tissue, we compared allele specific expression patterns between our AAA samples and  
 216 387 GTEx aortic samples, used as controls. The comparison between AAA and control samples  
 217 identified 1,815 genes with significant differences in the allele specific expression patterns  
 218 (adjusted p-value < 0.05) (**Figure 4A**). An enrichment analysis on GO terms for these 1,815

219 genes revealed 91 enriched pathways. The posterior cluster analysis revealed three clusters  
220 strongly related to the immune system: MHC protein complex, positive regulation of T cell-  
221 mediated cytotoxicity, and regulation of T cell activation (**Figure 4B**). The association between  
222 the immune system and AAA was also observed in the differential expression analysis between  
223 AAA samples and controls, validating the robustness of these results.

224 Finally, among the 90 genes that exhibited significant allele specific expression in more than  
225 five AAA samples, we selected those that also showed significant differential allelic specific  
226 expression analysis between AAA and GTEx control samples, and those present in loci  
227 identified in the largest genome-wide association study (GWAS) on AAA risk[7], in order to  
228 identify haplotypes associated with AAA risk. Among the selected genes, *SNURF* was the only  
229 gene that also presented differential allele specific expression patterns between AAA and  
230 control tissues, and *SPP1* and *THBS2* were prioritized based on their presence in a locus  
231 identified in the previous GWAS on AAA. This allowed to hypothesize that the presence of  
232 particular genetic haplotypes in these three genes determined their differential expression  
233 associated with risk of AAA.

## 234 **DISCUSSION:**

235 This study analyzes differential expression between AAA aortic tissue samples and control  
236 aortic samples using whole transcriptome data obtained through RNAseq. In addition, we  
237 studied the effect of ischemic time on gene expression, to obtain a more credible list of genes  
238 associated with AAA development. Using our RNAseq data, which provides superior alternative  
239 splicing analysis compared to microarrays[22], we conducted a novel exploration of alternative  
240 splicing between AAA and control samples, to identify potential causes of the observed  
241 differential expression. Furthermore, we analyzed the differential expression between AAA of  
242 different diameters to study the genes altered during disease progression. Finally, we analyzed

243 allele specific expression to gain insights into how genetic variants impact expression in the  
244 diseased tissue.

#### 245 Study of ischemic time-independent pathways involved in AAA development:

246 Clustering analysis with the enriched pathways after accounting for the ischemic time effect  
247 revealed a strong association with MHC class II protein complex, positive regulation of T-cells,  
248 and intracellular calcium ion regulation. Additionally, we have for the first time identified the  
249 regulation of the ATP synthesis pathway in a differential expression analysis of aortic samples.  
250 While the detection of the ATP synthesis regulatory pathway is novel, it is in line with previous  
251 work associating mitochondrial dysfunction and AAA [23,24]. On the other hand, previous  
252 differential expression studies in microarrays between AAA and control aortic tissue have  
253 consistently found associations of immune system pathways with AAA.[10–13,15] Our results  
254 confirm these associations and demonstrate that these are independent of the ischemic time,  
255 which is a confounder factor in most studies using donor samples. Finally, the regulation of  
256 intracellular calcium was previously detected in one study of differential expression between  
257 dilated and non-dilated aortic samples[11]. Our analyses confirm that this association is  
258 independent of ischemic time.

259 We identified for the first time several enriched signaling pathways, with a large presence of  
260 genes that code for subunits of complexes I (NADH ubiquinone oxidoreductase), III (Ubiquinol-  
261 cytochrome c reductase) and IV (cytochrome c oxidase)) of the electron transport chain. Our  
262 results indicate that 88 % (22 / 25) of the DEGs coding for the subunits of the complexes that  
263 form the electron transport chain are expressed to a lower extent in AAA, suggesting a lower  
264 synthesis of ATP in AAA tissue. Mitochondrial dysfunction has previously been studied in the  
265 development of AAA[23,24] and other cardiovascular diseases[25] due to its key role in some  
266 of the cellular alterations characteristic of cardiovascular diseases, including excessive  
267 production of reactive oxygen species, energy depletion, endoplasmic reticulum stress, and

268 activation of apoptosis. However, this is the first time that these metabolic pathways have been  
269 characterized in a DEGs study of AAA, confirming the role of mitochondrial dysfunction on AAA.

270 Among the genes present in all the enriched signaling pathways related to intracellular calcium  
271 regulation, *APLN*[26], *F2R*[27], *GPER1*[19], *JPH2*[28], *PKD2*[29] and *THY1/CD90*[30] have  
272 already been investigated for their role in AAA. However, six additional genes are present in all  
273 pathways: *ABL1*, *CALM1*, *CALM2*, *RYR2*, *SRI* and *CD19*. Except for *CALM2*, all of them have been  
274 previously identified as DEGs in previous microarray studies between AAA and control  
275 samples[10–12,15], but none of these genes have been further investigated in either functional  
276 or epidemiological studies. These genes are closely related to intracellular calcium metabolism.

277 *ABL1* participates in both the release of stored intracellular calcium and extracellular calcium  
278 entry[31]. *CALM1* and *CALM2* code for two isoforms of the calmodulin protein, which plays a  
279 crucial role in the contraction of vascular and cardiac tissue through the detection of  
280 intracellular calcium[32]. *RYR2* is mainly expressed in cardiac tissue and codes for the main  
281 regulator of sarcoplasmic calcium release[33]. *SRI* codes for the main binding protein of the  
282 *RYR2* gene product[34]. The comparison between our AAA and control samples shows a  
283 downregulation of all these genes, suggesting a decrease in intracellular calcium levels in  
284 smooth muscle cells, consistent with loss of vascular contractility in the dilated aorta[35].

285 On the other hand, we observed upregulation of the *CD19* gene in AAA. The activation of the  
286 surface protein encoded by *CD19* triggers the release of intracellular calcium, which contrasts  
287 with the previous results[36]. However, *CD19* is also a biomarker of B-cell development [36]  
288 which also play a key role in the development of AAA[37].

289 Among the pathways that were previously identified in differential expression analyses  
290 between AAA and control tissue is inflammation. There is a widely studied inflammatory  
291 component in AAA development involving both, adaptative and innate immune responses  
292 [17,18]. The presence of inflammatory infiltrates in AAA tissue have been widely

293 demonstrated, which play a key role in the development of the disease[17,18]. The results of  
294 our cluster analysis also corroborated the association with the immune system after accounting  
295 for ischemic time, highlighting the key role of T cells on AAA development[38,39].

296 To better understand the effects of the inflammatory infiltrate in AAA development, we  
297 compared the proportions of inflammatory infiltrates between AAA and control samples. Some  
298 previous studies have analyzed the inflammatory infiltrates in AAA tissue[15,19,40]. In one  
299 study[15], immune cell proportions were estimated in AAA tissue layers (media and adventitia),  
300 without comparing with controls. Our results strongly corroborate their findings, suggesting  
301 that plasma B cells and M2 macrophages were the two most represented cell populations in  
302 both layers, and M1 macrophages, eosinophils, and activated dendritic cells were among the  
303 least represented cells in both layers. Surprisingly, resting mast cells emerged as our third most  
304 represented cell group, while in the layer-specific analysis, mast cells represented a small  
305 percentage of the total inflammatory cells. This contrasts with another study that compared  
306 whole-tissue samples between AAA and controls[19], where resting mast cells were among the  
307 most frequent cell groups in AAA samples. In addition, our results align with this study in  
308 detecting higher proportions of CD8 T-cells and lower proportions of resting NK cells in AAA  
309 samples. However, a discrepancy was noted in the levels of activated dendritic cells, which  
310 were more present in controls in our study but slightly higher in AAA samples in the previous  
311 work. Additional single-cell data demonstrated a higher proportion of T follicular helper cells  
312 and lower proportions of M1 and M2 macrophages in AAA samples compared to controls[40].

313 To rule out the effect of death as potential cause of variability, we used a reference work that  
314 evaluated the effect of death in blood samples,[41] which found higher levels of resting NK  
315 cells and CD8 T-cells in post-mortem samples. These results suggest that the increase in CD8 T-  
316 cells levels in AAA tissue could be even greater than the one we observed, and that the greater  
317 presence of NK resting cells in control samples could be due, in part, to their origin from organ

318 donors. Consistent with this hypothesis, previous studies have shown that levels of NK cells are  
319 higher in the peripheral blood of AAA patients compared to controls,[42] and that these cells  
320 play a role in the development of the disease[18]. These results also suggest the existence of a  
321 highly cytotoxic environment led by CD8 T-cells in AAA tissue.

322 The lower levels of activated dendritic cells in the AAA samples compared to the controls was  
323 unexpected, given their established role as AAA inducers[17,19]. These results suggest that,  
324 although dendritic cells may participate in the development of AAA, they are not part of the  
325 inflammatory infiltrate.

#### 326 Study of alternative splicing between AAA and controls:

327 This is the first study to elucidate the role of splicing in AAA development. We compared splice  
328 events between AAA and controls and identified eleven genes (*SPP1*, *FHL1*, *GNAS*, *MORF4L2*,  
329 *HMG1*, *ARL1*, *RNASE4*, *ASAH1*, *CYCS*, *HMGB1*, *SELENOP*) with differentially represented  
330 splicing variants. We compared the splice events types identified in our comparison between  
331 AAA and controls samples with the presence of splicing events in the whole genome [21] and  
332 the observed proportions were comparable to the expected values genome-wide. The most  
333 frequent splicing types were alternative first exon (60 %) and skipping exon (20 %), while the  
334 least frequent were alternative 5' splice-site (13.3 %) and mutually exclusive exon (6.67 %). On  
335 the other hand, it was surprising that our results did not include alternative last exon,  
336 alternative 3' splice-site, and retained intron, despite their considerable genome-wide  
337 frequencies (10.72 %, 9.2 % and 3.54 %, respectively). This may be due to the limited sample  
338 size, as only 15 events were identified.

339 We observed seven genes that showed differential expression between AAA and control  
340 samples and had a splicing variant significantly more represented in AAA or controls (*SPP1*,  
341 *FHL1*, *GNAS*, *MORF4L2*, *HMG1*, *ARL1*, *RNASE4*), indicating that splicing differences could be  
342 explaining the observed differential expression. Among these genes, *SPP1* and *FHL1* have been

343 previously characterized in relation to AAA[43,44], whereas *GNAS* is a new DEG identified  
344 between AAA and control tissue. The evidence of differential splicing events validates *GNAS* as  
345 a new robust DEG between AAA and control tissue, and suggests that alternative splicing in this  
346 gene explains the differential expression and its implication to AAA. Finally, *MORF4L2*, *HMG1*,  
347 *ARL1* and *RNASE4* although they have been identified in previous differential expression  
348 studies in relation to AAA[10–15], their specific role in AAA has not been studied. For these  
349 genes, our results contribute to understand the molecular mechanism leading to differential  
350 expression in AAA tissue.

351 *SPP1* codes for the osteopontin protein, an important regulator of inflammation that has  
352 described functions in cardiovascular diseases[45]. *SPP1* is more expressed in AAA tissue than  
353 controls, both in animal models and in humans, and it participates in AAA-associated  
354 extracellular matrix degradation[46,47] through the nuclear factor kappa B signaling pathway.  
355 It is also known that the *SPP1* gene undergoes splicing and gives rise to 3 distinct isoforms  
356 osteopontin a, osteopontin b and osteopontin c, with specific characteristics, which have not  
357 been characterized in AAA. Consistent with previous data, our results found increased  
358 expression in AAA tissue, and identified for the first time that that skipping of exon 3 on *SPP1*  
359 gene is more frequent in AAA than in controls, suggesting that this form of alternative splicing  
360 may be important for the development of AAA.

361 *FHL1* codes for a protein that is highly expressed in skeletal and cardiac muscle. *FHL1* has been  
362 shown to be a promising blood biomarker for human ascending thoracic aortic aneurysm as a  
363 modulator of metalloproteases.[44] Our findings, and those obtained in previous microarray  
364 studies[10–13,15], indicate that *FHL1* levels are lower in AAA than in controls. We have  
365 detected for the first time that an alternative 5' splicing-site form in this gene occurs more  
366 frequently in the control group, suggesting that AAA tissue would have reduced expression of  
367 this alternative isoform and reduced levels of *FHL1*, leading to higher risk of AAA development.



Although not previously found in transcriptomic studies, mutations in the *GNAS* gene have been studied in mice for their effect promoting AAA[48]. *GNAS* codes for the alpha subunit of the heterotrimeric G stimulatory protein ( $G\alpha$ ).  $G\alpha$  may play a protective role in AAA development through regulation of vascular muscle tissue and is considered a potential therapeutic target[48]. Consistent with this protective role, our results confirmed lower expression *GNAS* levels in AAA. Moreover, our results add a mechanistic insight by revealing an alternative first exon splicing variant that occurs more frequently in controls and that could increase expression levels of the final protein and protect against AAA.

*MORF4L2* and *HMG1* are DNA repair related genes, which had significantly lower and higher expression levels in AAA tissue compared to control tissue, respectively. *MORF4L2* has been associated with atheroma plaque progression in atherosclerosis[49]. Both genes present alternative splicing events that are less frequent in AAA tissue. Further work to elucidate the specific role of these genes in the risk of AAA development is warranted.

#### Genes associated with AAA onset and progression:

We identified eight genes (*EXTL3*, *ZFR*, *DUSP8*, *DISP1*, *USP33*, *VPS37C*, *ZNF784*, *RFX1*) that showed differential expression between AAA and control tissues, and also differential expression in AAA tissues of different diameters. Among these, *EXTL3*, *ZFR*, *DUSP8*, and *DISP1* have been previously identified as DEGs between AAA and controls but their role in AAA progression is novel.[10–15], and *USP33*, *VPS37C*, *ZNF784* and *RFX1* are novel DEGs. This could indicate that the genes may have a role beyond the disease onset and could be potential therapeutic targets to halt aneurysm expansion. Therefore, the potential contribution of these genes to the development of AAA needs to be thoroughly investigated.

Among the genes with higher expression at larger diameters, *USP33* encodes a deubiquitinating enzyme that has been associated with the development of hypertension[50], a known risk factor for AAA[51]. Proteins with deubiquitinating functions have been proposed

393 as possible candidate genes for the treatment of AAA and other cardiovascular diseases[52].  
 394 Additionally, *USP33* promotes the stabilization of beta2-adrenergic receptors, which promote  
 395 vasodilation in smooth muscle[53]. We observed an increase in *USP33* expression with  
 396 increased AAA diameter, which is consistent with the functionality of beta2-adrenergic  
 397 receptors. These results suggest that the *USP33* gene may be a potential candidate for the  
 398 treatment of AAA.

399 Among the genes that exhibit lower expression levels with larger diameters, we highlight  
 400 *DUSP8* and *RFX1*. *DUSP8* is a phosphatase that negatively regulates the MAP kinase pathway,  
 401 which is linked to cell differentiation and proliferation[54]. Previous studies have shown that  
 402 *DUSP8* expression levels are downregulated in mouse models of aortic dilatation[55], and the  
 403 dual specificity phosphatase 8 protein (DUSP8) acts as a regulator of cardiac dynamics[54]. Our  
 404 findings align with those obtained in the animal model of aortic dilatation, suggesting that  
 405 *DUSP8* may be a potential candidate gene for treating AAA by regulating both aortic dilatation  
 406 and the immune system. *RFX1* encodes a transcription factor that regulates genes involved in  
 407 MHC class II[56]. In a previous bioinformatics study using microarray data, *RFX1* was identified  
 408 as a transcription factor that could potentially regulate DEGs between AAA and controls  
 409 through its downregulation[57]. Previous research has shown that a decrease in *RFX1*  
 410 expression leads to activation of CD14<sup>+</sup> monocytes in CAD patients[58]. Furthermore, CD14  
 411 protein plays a crucial role in recruiting macrophages during the early stages of AAA, and  
 412 knockout mice for *CD14* gene have been shown to resist the formation of AAA in two different  
 413 models[59]. Finally, our expression results indicate that *CD14* is upregulated in AAA patients  
 414 compared to controls (FDR P-value = 0.002). In conclusion, these results suggest that low  
 415 expression levels of the transcription factor *RFX1* may lead increased *CD14* expression, which  
 416 plays a crucial role in the development and progression of AAA by recruiting macrophages.

Two previous studies have considered the diameter of AAA in differential expression analyses with aortic tissues. The first study[10] compared gene expression between small (n = 20) and large AAA (n = 29) with controls, but did not compare AAA of varying diameters. The second study[15] performed a correlation analysis on each gene between the diameter growth rate and gene expression in individuals (n = 24) with two aortic measurements, distinguishing between the media and adventitia aortic layers but did not identify any significant genes after multiple testing correction. The larger sample size in our study have enabled to identify for the first time genes that are associated to aneurysm progression, which could be potential therapeutic targets.

#### Identification of haplotypes associated with AAA risk:

We performed a clustering analysis of enriched biological pathways with the 1,815 genes with significant differences in the allele specific expression patterns between AAA and controls. The cluster analysis revealed a strong association with immune system pathways, particularly those associated with T cells. These results are consistent with the clustering analysis of DEGs between AAA and controls and demonstrate how specific haplotypes determine the differential expression of genes associated with AAA in the diseased tissue. By combining allele specific expression information on AAA samples with the allelic specific expression results between AAA and controls, along with information from a previously published GWAS[7], we explored the associations between genetic variants associated with AAA risk and gene expression. This approach aimed to unravel the association between genetic haplotypes and gene expression as determinants of AAA risk.

*SNURF* is the only gene that showed significant allelic specific expression in more than five of the twelve studied individuals with AAA and differential allelic specific expression patterns between AAA and controls suggesting the existence of a specific haplotype associated with less expression in AAA and leading to higher risk of AAA. *SNURF* codes for an open reading frame of

the *SNRPN* gene, with which it forms a bicistronic gene[60]. Both genes exhibit significantly lower expression in AAA than in controls in our data. Moreover, we observed that rs705 single nucleotide polymorphism (SNP) (minor allele frequency (MAF) (C) = 0.45) determined *SNURF* expression in eight out of twelve AAA samples, where the T allele was associated with double expression amounts compared to the C allele. Additionally, rs705 is an eQTL in blood of the *SNRPN* gene. Although causality cannot be derived from these results, these results suggest a possible effect of the haplotype containing the rs705 T allele on this locus on *SNURF* expression, resulting in higher risk for AAA development.

Among the genes with significant allele specific expression in the twelve analyzed AAA samples that did not exhibit significant allele specific expression patterns between AAA and control groups in our analyses, we selected those that were part of a locus associated to AAA in the most recent GWAS on AAA risk[7]. *THBS2* encodes for thrombospondin 2, a protein that regulates cell-cell and cell-extracellular matrix interactions and has been studied in relation to multiple cardiovascular diseases[61]. *THBS1*, a member of the same family, has been identified as a regulator of AAA in animal models[62]. Our allele specific expression results suggest that the expression of this gene could be associated with AAA development, supporting the implication of the gene in AAA risk. Two common genetic variants (rs58023137 (MAF (T) = 0.22) and rs9505895 (MAF (A) = 0.2)) were identified in previous GWAS studies[7] and in our allele specific expression results. For both variants, the GWAS risk allele was associated with higher expression gene levels in one individual with AAA. Additionally, these two variants were also eQTLs in aortic tissue regulating *THBS2* gene expression, confirming the known association between thrombospondin and AAA[7], and demonstrating the presence of risk haplotypes associated to increased expression and risk of AAA.

Regarding the *SPP1* gene, we found six genetic variants (rs35893069 (MAF (T) = 0.1), rs6839524 (MAF (G) = 0.12), rs4754 (MAF (C) = 0.28), rs1126616 (MAF (T) = 0.27), rs1126772 (MAF (G) =

0.21), rs9138 (MAF (C) = 0.22)) with allele specific expression among the twelve AAA samples. As previously discussed, the *SPP1* has been associated to AAA risk due to the role of the protein osteopontin, which it encodes, in the degradation of the extracellular matrix that is characteristic of AAA[46,47]. However, none of the six genetic variants were found to be significant in the previous GWAS[7], and therefore no association with allelic expression could be established.

#### Strengths and limitations and comparison with previous studies

This is one of the largest studies of differential expression between AAA tissue samples and controls. However, due to the difficulty in obtaining aortic tissue samples, the sample size is still limited compared to transcriptomic studies in more accessible tissues, which may have limited our power. Previous studies comparing transcriptomics between AAA and control samples have been limited to the use of expression microarrays[10–15]. In this study, we used RNAseq to obtain transcriptomic information. RNAseq provides greater sensitivity, a wider range of detection of both high and low expression genes, and is not limited to microarray probes[9,63], which allowed us to detect more DEGs. Additionally, RNAseq technology allowed for a more precise study of alternative splicing compared to microarrays.

Accounting for ischemic time enabled us to more accurately identify biological processes associated to AAA, thereby minimizing differences in sample origins between AAA and controls. At the same time, despite ensuring more robust findings, the elimination of these genes could have been too rigorous and imply the loss of some biological pathways associated with AAA that, at the same time were affected by ischemic time.

The significant phenotypic differences in age and sex between individuals recruited as AAA and controls are a limitation of the study. Moreover, the analyses of the allele specific expression are limited by the small sample size (n = 12) and the requirement for the individuals to be heterozygous in order to study the genetic variants. Therefore, further validation is necessary.

492 However, this is the first study analyzing allele specific expression in AAA and our results  
493 emphasize the value of this new dataset combining genetic and expression data for the study  
494 of AAA.

495 Finally, the conclusions presented in this article are based on the results obtained from a  
496 cohort of European- ancestry individuals only. Further analyses in different ancestries will  
497 determine the generalization of these results.

## 498 **CONCLUSIONS**

499 Our analysis of the whole transcriptome has enabled us to identify numerous novel genes that  
500 were not previously detected in microarray studies. Additionally, our efforts to account for the  
501 impact of ischemic time have provided more robust implicated biological pathways that lead to  
502 AAA development. Among these pathways, ATP synthesis regulation (i.e. genes encoding  
503 subunits I, III and IV of the electron transport chain), has been associated for the first time in  
504 transcriptomic studies of AAA tissue, although this pathway was previously studied in relation  
505 to AAA in previous studies[23,24]. Additionally, the study of differential splicing processes  
506 between AAA and controls have revealed novel molecular processes involving already known  
507 genes in relation to AAA, such as *SPP1*, *FHL1* or *GNAS*.

508 The study also analyzed the differential expression of genes in individuals with AAA of different  
509 diameters, providing valuable insights into the underlying molecular mechanisms contributing  
510 to AAA progression. Further research on these genes may lead to potential treatments against  
511 aneurysm expansion, which increases the risk of rupture. Finally, the analysis of differential  
512 allele specific expression in twelve AAA has allowed the identification of haplotypes associated  
513 with expression of certain genes and AAA risk, providing evidence for their involvement in  
514 disease, and shedding light into the molecular mechanism.

515 Overall, this study provides a comprehensive exploration of AAA expression patterns, revealing  
516 key insights into the pathophysiology of AAA initiation and progression. RNAseq was used to

517 conduct one of the largest differential expression analyses to date, uncovering numerous genes  
518 associated with AAA. Our consideration of ischemic time and AAA diameter improved the  
519 precision in identifying biological processes associated with AAA onset and progression.  
520 Furthermore, our analysis of differential allele specific expression has identified genetic  
521 haplotypes that influence gene expression on AAA tissue, which advances our understanding of  
522 AAA genetic background. These findings contribute to future research and potential advances  
523 in precision medicine to reduce AAA progression and mortality risk.

## 524 **METHODS:**

### 525 Subjects:

526 We used a total of 140 human abdominal aortic samples from 96 patients diagnosed with  
527 infrarenal AAA and undergoing open surgery for AAA repair at *Hospital de la Santa Creu i Sant*  
528 *Pau* and *Hospital del Mar* (Barcelona) and 44 controls. The study participants were obtained  
529 from TABS cohort, which includes genomic, transcriptomic, clinical, and maximum aneurysm  
530 size data, from AAA patients and healthy individuals. Maximum aortic diameters were obtained  
531 from computed tomography or ultrasound images. Genomic data were obtained through  
532 genotyping using the Infinium Global Screening Array-24 v2.0 from Illumina (San Diego,  
533 California) (coverage 665,608 variants) and imputation to the TOPMED Reference Panel. Only  
534 variants with imputation quality > 0.3 were used for the allele specific expression analyses.  
535 Healthy abdominal aortas were obtained from 21 male and 23 female multiorgan donors  
536 (**Table 1**).

### 537 Sample processing:

538 A portion of tissue sample was placed in RNeasy lysis solution (Qiagen GmbH, Hilden, Germany)  
539 and stored for 24 hours at 4 °C before long-term storage at -80 °C until further processing. For  
540 RNA isolation, tissues were then homogenized in 1 ml Trizol (Ambion, Carlsbad, CA) in the  
541 FastPrep-24 homogenizer and Lysing Matrix D tubes (MP Biomedicals, Solon, OH) and RNA was

542 purified using PureLink RNA Mini Kit (Invitrogen, Carlsberg) following the manufacturer's  
543 recommendations. RNA concentration was measured using Nanodrop 200 (Thermo Scientific).  
544 RNA integrity was assessed on Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). RNA  
545 integrity number (RIN) was recorded and only samples with a RIN higher than 6 were used.

#### 546 RNA sequencing:

547 We performed sequencing analyses using Illumina NovaSeq 6000, with a read length of 150 bp  
548 and paired-end sequencing. Two sequencing runs were performed to reduce the variability of  
549 the technical variables. First, AAA and control samples were randomized between sequencing  
550 plates. Second, only AAA were sequenced with as little technical variability as possible. In all  
551 sequencing runs, a minimum of 30 million reads were required, repeating the sequencing on a  
552 new plate if this limit was not reached.

#### 553 Alignment, quantification, and quality control:

554 We used STAR v.2.5.3a[64] to perform the alignment on the reference genome version GRCh38  
555 and we then used RSEM v1.3.0[65] for gene quantification. For both analyses, we used gene  
556 models from GENCODE v26 gene annotation file[66]. In total, 58,219 genes were quantified. Of  
557 these, we selected protein coding genes and long non-coding RNA (lncRNA) genes that had  
558 been either experimentally validated (level 1 annotation) or manually annotated (level 2  
559 annotation)[66], resulting in 27,290 genes (19,777 protein-coding and 7,513 lncRNA) for  
560 further analyses. Gene quantifications were expressed as Transcripts Per Million (TPMs), which  
561 were obtained by normalizing for gene length first, and then for sequencing depth. This  
562 ensured that the sum of all TPMs in each sample was the same, facilitating the comparison  
563 between samples. All samples reached a minimum of 10 million reads aligned to the reference  
564 genome with STAR (**Additional file 1: Figure S5A-5B**)[64].



As part of the quality control, we also checked that the reported sex of the samples matched the biological sex of the sequenced data. To do this, we compared the expression levels of the *XIST* gene, which regulates the X chromosome inactivation mechanism in females and has null expression in males, with the expression of male exclusive genes, calculating an average expression of Y chromosome genes. One sex mismatch sample was eliminated from the study (**Additional file 1: Figure S5C**).

#### Differential expression analysis:

Before conducting differential expression analyses, we normalized the TPMs counts using quantile normalization and removed lowly expressed genes by removing genes with less than 0.5 TPMs in more than 50% of the samples. For the comparison of AAA against control samples, we kept 14,675 genes and removed 12,615 genes. For the comparisons among AAA using the AAA-only sequencing panel, we kept 14,779 genes and removed 12,511 genes.

To evaluate the impact of technical covariates on the results, we performed a Principal Components (PC) Analysis on all samples and tested the correlation between the PC Analysis and all the technical covariates. Technical covariates that had significant correlations (p-value < 0.05) with the first four PC were included in the analyses as fixed effect covariates. Additionally, all comparisons were adjusted for age and sex. To preserve the regulatory effects that act through smoking, we did not include smoking as a covariate (**Additional file 10: Table S9**).

First, we calculated DEGs between AAA and controls using a linear regression, including age, sex, flow cell type, flow cell lane, GC mean content (GC mean), RIN, percentage of RNA fragments > 200 (DV200), and Qubit as covariates. Date of creation of the library was not included due to its high correlation with the case/control variable (Pearson's correlation = -0.74) (**Additional file 1: Figure S6A-6B**). Second, we calculated DEGs between aneurysms of varying diameter using a linear regression, including age, sex, date of creation of the library, batch number, GC mean, RIN, DV200 and Qubit. We corrected for multiple testing in both

590 analyses using Benjamini-Hochberg false discovery rate (FDR) method and considered  
591 significant DEGs those with an adjusted p-value below 0.05[67].

592 We then performed a linear regression model to identify genes whose expression could be  
593 altered by ischemic time, using ischemic time information on artery aorta tissue samples from  
594 GTEx V8 data[16]. We corrected the linear regression model for age, sex, RIN, type 2 diabetes,  
595 body mass index, autolysis score, center, sequencing protocol, sequencing platform, and  
596 genotyping PC. To determine the genes affected by ischemic time, we corrected for multiple  
597 testing and selected genes with an FDR-adjusted p-value lower than 0.05[67]. All analyses were  
598 performed in R.

#### 599 Enrichment analysis:

600 After identifying DEGs between AAA and control samples and between AAA of varying  
601 diameters, we performed enrichment analyses using the R package ‘clusterprofiler’[68,69] on  
602 the Gene Ontology (GO) databases for Biological Process, Cellular Component and Molecular  
603 Function, as well as the Kyoto Encyclopedia of Genes and Genomes (KEGG)[70]. We corrected  
604 for multiple testing using the Benjamini-Hochberg FDR method and identified significantly  
605 enriched pathways with an adjusted p-value below 0.05[71]. We used ‘aPEAR’[72] to perform a  
606 cluster analysis of redundant pathways with a minimum cluster of size of 15 and hierarchical  
607 clustering. The enriched pathways and genes were visualized using ‘enrichplot’[73].

#### 608 Study of the inflammatory infiltrate:

609 We investigated the differences in the proportions of inflammatory infiltrates between AAA  
610 and control samples using CIBERSORTx[74]. CIBERSORTx compares RNAseq data with a  
611 reference expression database of selected cell types, to estimate the proportion of each cell  
612 type. The residuals of our RNA-seq data were calculated using a linear regression that included  
613 all covariates except the status variable. We used the residuals and the ‘lm22’ signature matrix,  
614 that contains expression data of 547 genes in 22 inflammatory cell types from microarray

615 studies, and can be used to distinguish inflammatory cell populations in RNA-seq data[74]. We  
616 conducted a t-test to compare the proportions of each cell type between AAA and controls. A  
617 p-value threshold corrected by multiple testing using Bonferroni for the number of cell types  
618 was set at  $p\text{-value} < 2.27 \times 10^{-3}$  ( $0.05 / 22$ ).

#### 619 Alternative splicing:

620 We used the SUPPA2 software to identify differences in splice events between AAA and control  
621 tissue samples. SUPPA2 can identify seven different splice events including skipping exons,  
622 mutually exclusive exons, alternative 5' or 3' splice sites, retained introns, and alternative first  
623 or last exons. Based on gene annotation from GENCODE v26,[66] we computed the proportion  
624 of splice inclusion for the TPMs counts in each splice event by dividing the number of TPMs of  
625 one form of the event by the total number of TPMs. Finally, the magnitude of splicing change  
626 was calculated by subtracting the proportion of splice inclusions between AAA and controls.  
627 Significant alternative splicing events were selected based on a magnitude of splicing change  
628 higher than 0.1 and FDR-corrected p-values lower than 0.05, using the default parameters for  
629 calculation.

#### 630 Allelic specific expression:

631 Allele specific expression was investigated using PHASER[75] on twelve AAA samples with  
632 genotype data. Allele specific expression consists of the analysis of the differences in the  
633 expression levels of the different haplotypes present in a heterozygous individual. We  
634 quantified allele specific expression at the gene level using the GENCODE V26 gene  
635 annotation[66]. To reduce the effect of the known mapping bias towards the reference  
636 allele[76], we performed an additional STAR mapping step with WASP filtering[77].

637 We used the allele specific expression data obtained by the GTEx consortium to compare allele  
638 specific expression between our AAA samples and GTEx control tissues[78]. To do this, we  
639 compared the proportional expression of each allele between our AAA samples and the GTEx

640 controls, using a non-parametric Wilcoxon test[79]. Then, to identify genes with distinct allele  
641 specific expression patterns, we corrected for multiple comparisons using FDR[67]. We  
642 performed enrichment and cluster analyses in all genes showing FDR adjusted p-values lower  
643 than 0.05.

## 644 ABBREVIATIONS

645 **AAA** abdominal aortic aneurysm  
646 **DEGs** differentially expressed genes  
647 **TABS** triple A Barcelona study  
648 **LncRNA** long non-coding RNA  
649 **TPMs** transcripts per million  
650 **PC** principal component  
651 **GC mean** GC mean content  
652 **DV200** percentage of RNA fragments > 200  
653 **FDR** false discovery rate  
654 **GO** gene ontology  
655 **KEGG** Kyoto encyclopedia of genes  
656 **MHC** major histocompatibility complex  
657 **GWAS** genome-wide association study  
658 **ATP** adenosine triphosphate  
659 **G $\alpha$**  heterotrimeric G stimulatory protein  
660 **DUSP8** dual specificity phosphatase 8 protein

661 **SNP** single nucleotide polymorphism

662 **MAF** minor allele frequency

## 663 **DECLARATIONS**

### 664 Ethics approval and consent to participate:

665 The study was approved by the *Hospital de la Santa Creu i Sant Pau* Ethics Committee (IIBSP-  
666 OMI-2019-102). All patients gave written informed consent prior to surgery to participate in  
667 the study. The study conformed to the principles of the Declaration of Helsinki.

### 668 Consent for publication:

669 Not applicable.

### 670 Availability of data and materials:

671 The personal data used for this study is available from the corresponding author on reasonable  
672 request for collaborations provided it complies with the ethical permits of the study. All other  
673 data supporting the findings of this study is available within the paper and its Supplementary  
674 Information. Code used for data preparation and analysis is available at  
675 <https://github.com/Gerardts9/RNAseq>.

### 676 Competing interests:

677 The authors declare that they have no competing interests.

### 678 Funding:

679 This work was supported by a grant from the Spanish Ministry of Science and  
680 Innovation (PID2019-109844RB-I00). The genotyping service was carried out at the Genotyping  
681 Unit-CEGEN in the Spanish National Cancer Research Centre (CNIO), supported by Instituto de  
682 Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación. CEGEN is part of the initiative

IMPACT-GENÓMICA (IMP/00009) cofunded by ISCIII and the European Regional Development Fund (ERDF). GT-S is supported by the Pla Estratègic de Recerca i Innovació en Salut (PERIS) grant from the Catalan Department of Health for junior research personnel (SLT017/20/000100). MS-L is supported by a Miguel Servet contract from the ISCIII Spanish Health Institute (CPII22/00007) and co-financed by the European Social Fund. DD was funded by a Tenovus Scotland Research PhD studentship, T19-06.

#### Author's contributions:

AV, MC, and MS-L conceived and designed the study. BS, JD, OP, LC, LN and J-RE generated the clinical database and supplied the samples. GT-S and DD performed the analyses. GT-S, AB, AV, MC, and MS-L interpreted the results. GT-S, AV, MC, and MS-L wrote the manuscript. All authors read and approved the final manuscript.

#### Acknowledgments:

We acknowledge the AAA patients at *Hospital de la Santa Creu i Sant Pau* and *Hospital del Mar* who participated in this study, and the multiorgan donor families who made this research possible through their generous consent.

#### Author's information:

AV, MC, and MS-L contributed equally to this work as senior authors.

## **REFERENCES**

1. Aggarwal S, Qamar A, Sharma V, Sharma A. Abdominal aortic aneurysm: A comprehensive review. *Exp Clin Cardiol* 2011;16:11–5.
2. Kuivaniemi H, Ryer EJ, Elmore JR, Tromp G. Understanding the pathogenesis of abdominal aortic aneurysms. *Expert Review of Cardiovascular Therapy* 2015;13:975–87.
3. Holmes DR, Liao S, Parks WC, Thompson RW. Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. *J Vasc Surg* 1995;21:761–71; discussion 771-772.

- 708 4. Robinson WP, Schanzer A, Li Y, Goodney PP, Nolan BW, Eslami MH, et al. Derivation and  
709 validation of a practical risk score for prediction of mortality after open repair of ruptured  
710 abdominal aortic aneurysms in a U.S. regional cohort and comparison to existing scoring  
711 systems. *J Vasc Surg* 2013;57:354–61.
- 712 5. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, et al. The  
713 Society for Vascular Surgery practice guidelines on the care of patients with an abdominal  
714 aortic aneurysm. *Journal of Vascular Surgery* 2018;67:2-77.e2.
- 715 6. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, et al. The Aneurysm  
716 Detection and Management Study Screening Program: Validation Cohort and Final  
717 Results. *Archives of Internal Medicine* 2000;160:1425–30.
- 718 7. Roychowdhury T, Klarin D, Levin MG, Spin JM, Rhee YH, Deng A, et al. Genome-wide  
719 association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights  
720 PCSK9 as a therapeutic target. *Nat Genet* 2023;55:1831–42.
- 721 8. Lowe R, Shirley N, Bleackley M, Dolan S, Shafee T. Transcriptomics technologies. *PLoS*  
722 *Comput Biol* 2017;13:e1005457.
- 723 9. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat*  
724 *Rev Genet* 2009;10:57–63.
- 725 10. Biros E, Gäbel G, Moran CS, Schreurs C, Lindeman JHN, Walker PJ, et al. Differential gene  
726 expression in human abdominal aortic aneurysm and aortic occlusive disease. *Oncotarget*  
727 2015;6:12984–96.
- 728 11. Lenk GM, Tromp G, Weinsheimer S, Gatalica Z, Berguer R, Kuivaniemi H. Whole genome  
729 expression profiling reveals a significant role for immune function in human abdominal  
730 aortic aneurysms. *BMC Genomics* 2007;8:237.
- 731 12. Biros E, Moran CS, Rush CM, Gäbel G, Schreurs C, Lindeman JHN, et al. Differential gene  
732 expression in the proximal neck of human abdominal aortic aneurysm. *Atherosclerosis*  
733 2014;233:211–8.
- 734 13. Choke E, Cockerill GW, Laing K, Dawson J, Wilson WRW, Loftus IM, et al. Whole Genome-  
735 expression Profiling Reveals a Role for Immune and Inflammatory Response in Abdominal  
736 Aortic Aneurysm Rupture. *European Journal of Vascular and Endovascular Surgery*  
737 2009;37:305–10.
- 738 14. Gäbel G, Northoff BH, Weinzierl I, Ludwig S, Hinterseher I, Wilfert W, et al. Molecular  
739 Fingerprint for Terminal Abdominal Aortic Aneurysm Disease. *J Am Heart Assoc*  
740 2017;6:e006798.
- 741 15. Lindquist Liljeqvist M, Hultgren R, Bergman O, Villard C, Kronqvist M, Eriksson P, et al.  
742 Tunica-Specific Transcriptome of Abdominal Aortic Aneurysm and the Effect of  
743 Intraluminal Thrombus, Smoking, and Diameter Growth Rate. *Arteriosclerosis,*  
744 *Thrombosis, and Vascular Biology* 2020;40:2700–13.
- 745 16. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science*  
746 2020;369:1318–30.

- 747 17. Márquez-Sánchez AC, Koltsova EK. Immune and inflammatory mechanisms of abdominal  
748 aortic aneurysm. *Front Immunol* 2022;13:989933.
- 749 18. Yuan Z, Lu Y, Wei J, Wu J, Yang J, Cai Z. Abdominal Aortic Aneurysm: Roles of Inflammatory  
750 Cells. *Frontiers in Immunology* [Internet] 2021 [cited 2022 Jan 25];11. Available from:  
751 <https://www.frontiersin.org/article/10.3389/fimmu.2020.609161>
- 752 19. Nie H, Qiu J, Wen S, Zhou W. Combining Bioinformatics Techniques to Study the Key  
753 Immune-Related Genes in Abdominal Aortic Aneurysm. *Front Genet* 2020;11:579215.
- 754 20. Hasimbegovic E, Schweiger V, Kastner N, Spannbauer A, Traxler D, Lukovic D, et al.  
755 Alternative Splicing in Cardiovascular Disease—A Survey of Recent Findings. *Genes (Basel)*  
756 2021;12:1457.
- 757 21. Rotival M, Quach H, Quintana-Murci L. Defining the genetic and evolutionary architecture  
758 of alternative splicing in response to infection. *Nat Commun* 2019;10:1671.
- 759 22. Romero JP, Ortiz-Estévez M, Muniategui A, Carrancio S, de Miguel FJ, Carazo F, et al.  
760 Comparison of RNA-seq and microarray platforms for splice event detection using a cross-  
761 platform algorithm. *BMC Genomics* 2018;19:703.
- 762 23. Ouyang M, Wang M, Yu B. Aberrant Mitochondrial Dynamics: An Emerging Pathogenic  
763 Driver of Abdominal Aortic Aneurysm. *Cardiovasc Ther* 2021;2021:6615400.
- 764 24. Summerhill VI, Sukhorukov VN, Eid AH, Nedosugova LV, Sobenin IA, Orekhov AN.  
765 Pathophysiological Aspects of the Development of Abdominal Aortic Aneurysm with a  
766 Special Focus on Mitochondrial Dysfunction and Genetic Associations. *Biomolecular*  
767 *Concepts* 2021;12:55–67.
- 768 25. Chistiakov DA, Shkurat TP, Melnichenko AA, Grechko AV, Orekhov AN. The role of  
769 mitochondrial dysfunction in cardiovascular disease: a brief review. *Annals of Medicine*  
770 2018;50:121–7.
- 771 26. Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA, et al. Apelin  
772 prevents aortic aneurysm formation by inhibiting macrophage inflammation. *American*  
773 *Journal of Physiology-Heart and Circulatory Physiology* 2009;296:H1329–35.
- 774 27. Shin SJ, Hang HT, Thang BQ, Shimoda T, Sakamoto H, Osaka M, et al. Role of PAR1-Egr1 in  
775 the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice. *Arteriosclerosis,*  
776 *Thrombosis, and Vascular Biology* 2020;40:1905–17.
- 777 28. Wang S, Liu H, Yang P, Wang Z, Ye P, Xia J, et al. A role of inflammaging in aortic aneurysm:  
778 new insights from bioinformatics analysis. *Frontiers in Immunology* [Internet] 2023 [cited  
779 2023 Dec 17];14. Available from:  
780 <https://www.frontiersin.org/articles/10.3389/fimmu.2023.1260688>
- 781 29. Sung PH, Yang YH, Chiang HJ, Chiang JY, Chen CJ, Liu CT, et al. Risk of aortic aneurysm and  
782 dissection in patients with autosomal-dominant polycystic kidney disease: a nationwide  
783 population-based cohort study. *Oncotarget* 2017;8:57594–604.
- 784 30. Kugo H, Moriyama T, Zaima N. The role of perivascular adipose tissue in the appearance  
785 of ectopic adipocytes in the abdominal aortic aneurysmal wall. *Adipocyte* 2019;8:229–39.



- 786 31. Chislock EM, Pendergast AM. Abl Family Kinases Regulate Endothelial Barrier Function In  
787 Vitro and in Mice. PLoS One 2013;8:e85231.
- 788 32. Beghi S, Furmanik M, Jaminon A, Veltrop R, Rapp N, Wichapong K, et al. Calcium  
789 Signalling in Heart and Vessels: Role of Calmodulin and Downstream Calmodulin-  
790 Dependent Protein Kinases. Int J Mol Sci 2022;23:16139.
- 791 33. Bround MJ, Wambolt R, Luciani DS, Kulpa JE, Rodrigues B, Brownsey RW, et al.  
792 Cardiomyocyte ATP Production, Metabolic Flexibility, and Survival Require Calcium Flux  
793 through Cardiac Ryanodine Receptors in Vivo. J Biol Chem 2013;288:18975–86.
- 794 34. Colotti G, Poser E, Fiorillo A, Genovese I, Chiarini V, Ilari A. Sorcin, a Calcium Binding  
795 Protein Involved in the Multidrug Resistance Mechanisms in Cancer Cells. Molecules  
796 2014;19:13976–89.
- 797 35. Sanders KM. Invited Review: Mechanisms of calcium handling in smooth muscles.  
798 Journal of Applied Physiology 2001;91:1438–49.
- 799 36. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis  
800 and therapy. Experimental Hematology & Oncology 2012;1:36.
- 801 37. Zhang L, Wang Y. B lymphocytes in abdominal aortic aneurysms. Atherosclerosis  
802 2015;242:311–7.
- 803 38. Forester ND, Cruickshank SM, Scott DJA, Carding SR. Functional characterization of T cells  
804 in abdominal aortic aneurysms. Immunology 2005;115:262–70.
- 805 39. Sagan A, Mikolajczyk TP, Mrowiecki W, MacRitchie N, Daly K, Meldrum A, et al. T Cells Are  
806 Dominant Population in Human Abdominal Aortic Aneurysms and Their Infiltration in the  
807 Perivascular Tissue Correlates With Disease Severity. Frontiers in Immunology [Internet]  
808 2019 [cited 2024 Feb 9];10. Available from:  
809 <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01979>
- 810 40. Xiong T, Lv XS, Wu GJ, Guo YX, Liu C, Hou FX, et al. Single-Cell Sequencing Analysis and  
811 Multiple Machine Learning Methods Identified GOS2 and HPSE as Novel Biomarkers for  
812 Abdominal Aortic Aneurysm. Front Immunol 2022;13:907309.
- 813 41. Ferreira PG, Muñoz-Aguirre M, Reverter F, Sá Godinho CP, Sousa A, Amadoz A, et al. The  
814 effects of death and post-mortem cold ischemia on human tissue transcriptomes. Nat  
815 Commun 2018;9:490.
- 816 42. Forester ND, Cruickshank SM, Scott DJA, Carding SR. Increased natural killer cell activity in  
817 patients with an abdominal aortic aneurysm. British Journal of Surgery 2006;93:46–54.
- 818 43. Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, et al. Association  
819 Between Osteopontin and Human Abdominal Aortic Aneurysm. Arteriosclerosis,  
820 Thrombosis, and Vascular Biology 2007;27:655–60.
- 821 44. Black KM, Masuzawa A, Hagberg RC, Khabbaz KR, Trovato ME, Rettagliati VM, et al.  
822 Preliminary Biomarkers for Identification of Human Ascending Thoracic Aortic Aneurysm.  
823 J Am Heart Assoc 2013;2:e000138.

- 824 45. Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin.  
825 Clinical Biochemistry 2018;59:17–24.
- 826 46. Wang SK, Green LA, Gutwein AR, Gupta AK, Babbey CM, Motaganahalli RL, et al.  
827 Osteopontin may be a driver of abdominal aortic aneurysm formation. Journal of Vascular  
828 Surgery 2018;68:225-295.
- 829 47. Liu H, Zhang Y, Song W, Sun Y, Jiang Y. Osteopontin N-Terminal Function in an Abdominal  
830 Aortic Aneurysm From Apolipoprotein E-Deficient Mice. Frontiers in Cell and  
831 Developmental Biology [Internet] 2021 [cited 2023 Nov 22];9. Available from:  
832 <https://www.frontiersin.org/articles/10.3389/fcell.2021.681790>
- 833 48. Qin X, He L, Tian M, Hu P, Yang J, Lu H, et al. Smooth muscle-specific Gsα deletion  
834 exaggerates angiotensin II-induced abdominal aortic aneurysm formation in mice in vivo.  
835 J Mol Cell Cardiol 2019;132:49–59.
- 836 49. Zhang R, Ji Z, Yao Y, Zuo W, Yang M, Qu Y, et al. Identification of hub genes in unstable  
837 atherosclerotic plaque by conjoint analysis of bioinformatics. Life Sciences  
838 2020;262:118517.
- 839 50. Greene D, Pirri D, Frudd K, Sackey E, Al-Owain M, Giese APJ, et al. Genetic association  
840 analysis of 77,539 genomes reveals rare disease etiologies. Nat Med 2023;29:679–88.
- 841 51. Kobeissi E, Hibino M, Pan H, Aune D. Blood pressure, hypertension and the risk of  
842 abdominal aortic aneurysms: a systematic review and meta-analysis of cohort studies.  
843 Eur J Epidemiol 2019;34:547–55.
- 844 52. Wang B, Cai W, Ai D, Zhang X, Yao L. The Role of Deubiquitinases in Vascular Diseases. J. of  
845 Cardiovasc. Trans. Res. 2020;13:131–41.
- 846 53. Johnson M. Molecular mechanisms of β2-adrenergic receptor function, response, and  
847 regulation. Journal of Allergy and Clinical Immunology 2006;117:18–24.
- 848 54. Ding T, Zhou Y, Long R, Chen C, Zhao J, Cui P, et al. DUSP8 phosphatase: structure,  
849 functions, expression regulation and the role in human diseases. Cell & Bioscience  
850 2019;9:70.
- 851 55. Baldo G, Wu S, Howe RA, Ramamoothy M, Knutsen RH, Fang J, et al. Pathogenesis of  
852 aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation.  
853 Mol Genet Metab 2011;104:608–19.
- 854 56. Emery P, Durand B, Mach B, Reith W. RFX proteins, a novel family of DNA binding proteins  
855 conserved in the eukaryotic kingdom. Nucleic Acids Res 1996;24:803–7.
- 856 57. Liu Y, Wang X, Wang H, Hu T. Identification of key genes and pathways in abdominal aortic  
857 aneurysm by integrated bioinformatics analysis. J Int Med Res  
858 2020;48:0300060519894437.
- 859 58. Du P, Gao K, Cao Y, Yang S, Wang Y, Guo R, et al. RFX1 downregulation contributes to TLR4  
860 overexpression in CD14+ monocytes via epigenetic mechanisms in coronary artery  
861 disease. Clin Epigenetics 2019;11:44.

- 862 59. Blomkalns AL, Gavrilu D, Thomas M, Neltner BS, Blanco VM, Benjamin SB, et al. CD14  
863 Directs Adventitial Macrophage Precursor Recruitment: Role in Early Abdominal Aortic  
864 Aneurysm Formation. *J Am Heart Assoc* 2013;2:e000065.
- 865 60. An imprinted, mammalian bicistronic transcript encodes two independent proteins |  
866 PNAS [Internet]. [cited 2024 Feb 12];Available from:  
867 <https://www.pnas.org/doi/10.1073/pnas.96.10.5616>
- 868 61. Zhang K, Li M, Yin L, Fu G, Liu Z. Role of thrombospondin-1 and thrombospondin-2 in  
869 cardiovascular diseases (Review). *Int J Mol Med* 2020;45:1275–93.
- 870 62. Liu Z, Morgan S, Ren J, Wang Q, Annis DS, Mosher DF, et al. Thrombospondin-1 (TSP1)  
871 Contributes to the Development of Vascular Inflammation by Regulating Monocytic Cell  
872 Motility in Mouse Models of Abdominal Aortic Aneurysm. *Circulation Research*  
873 2015;117:129–41.
- 874 63. Wang C, Gong B, Bushel PR, Thierry-Mieg J, Thierry-Mieg D, Xu J, et al. A comprehensive  
875 study design reveals treatment- and transcript abundance–dependent concordance  
876 between RNA-seq and microarray data. *Nat Biotechnol* 2014;32:926–32.
- 877 64. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast  
878 universal RNA-seq aligner. *Bioinformatics* 2013;29:15–21.
- 879 65. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or  
880 without a reference genome. *BMC Bioinformatics* 2011;12:323.
- 881 66. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE:  
882 The reference human genome annotation for The ENCODE Project. *Genome Res*  
883 2012;22:1760–74.
- 884 67. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful  
885 Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B*  
886 (Methodological) 1995;57:289–300.
- 887 68. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R Package for Comparing Biological  
888 Themes Among Gene Clusters. *OMICS* 2012;16:284–7.
- 889 69. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set  
890 enrichment analysis: A knowledge-based approach for interpreting genome-wide  
891 expression profiles. *Proceedings of the National Academy of Sciences* 2005;102:15545–  
892 50.
- 893 70. KEGG: new perspectives on genomes, pathways, diseases and drugs | Nucleic Acids  
894 Research | Oxford Academic [Internet]. [cited 2023 Apr 27];Available from:  
895 <https://academic.oup.com/nar/article/45/D1/D353/2605697>
- 896 71. Storey JD. A Direct Approach to False Discovery Rates. *Journal of the Royal Statistical*  
897 *Society. Series B (Statistical Methodology)* 2002;64:479–98.
- 898 72. Kersevičute I, Gordevicius J. aPEAR: an R package for autonomous visualization of  
899 pathway enrichment networks. *Bioinformatics* 2023;39:btad672.

- 900 73. Yu G, Hu E, Gao CH. enrichplot: Visualization of Functional Enrichment Result [Internet].  
901 2023 [cited 2023 Nov 21];Available from: <https://bioconductor.org/packages/enrichplot/>
- 902 74. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating  
903 immune cells with CIBERSORT. *Methods Mol Biol* 2018;1711:243–59.
- 904 75. Castel SE, Mohammadi P, Chung WK, Shen Y, Lappalainen T. Rare variant phasing and  
905 haplotypic expression from RNA sequencing with phASER. *Nat Commun* 2016;7:12817.
- 906 76. Degner JF, Marioni JC, Pai AA, Pickrell JK, Nkadori E, Gilad Y, et al. Effect of read-mapping  
907 biases on detecting allele-specific expression from RNA-sequencing data. *Bioinformatics*  
908 2009;25:3207–12.
- 909 77. van de Geijn B, McVicker G, Gilad Y, Pritchard JK. WASP: allele-specific software for robust  
910 molecular quantitative trait locus discovery. *Nat Methods* 2015;12:1061–3.
- 911 78. Castel SE, Aguet F, Mohammadi P, Aguet F, Anand S, Ardlie KG, et al. A vast resource of  
912 allelic expression data spanning human tissues. *Genome Biology* 2020;21:234.
- 913 79. van Beek D, Verdonschot J, Derks K, Brunner H, de Kok TM, Arts ICW, et al. Allele-specific  
914 expression analysis for complex genetic phenotypes applied to a unique dilated  
915 cardiomyopathy cohort. *Sci Rep* 2023;13:564.

## 916 **FIGURE LEGENDS**

### 917 **Figure 1**

918 Study design flowchart.

### 919 **Figure 2**

920 Hierarchical clustering analysis results with all the DEGs between AAA and controls (A) and  
921 after removing DEG by ischemic time (B). C) Comparison of the proportion of inflammatory  
922 cells between AAA and controls using CIBERSORTx.

### 923 **Figure 3**

924 A) Significant alternative splicing types identified between AAA and controls. B) Venn diagram  
925 showing the overlap between DEGs in AAA and controls and genes with differential alternative  
926 splicing patterns in AAA and controls. C) Venn diagram showing the overlap between DEGs in  
927 AAA and controls and DEGs by AAA diameter.

### 928 **Figure 4**

929 A) Results of PC analysis clustering between AAA and controls. B) Hierarchical clustering  
930 analysis results with genes with different allelic specific patterns between AAA and controls.

# 931 SUPPLEMENTARY INFORMATION

932 **Additional file 1:** Figures S1-S6

933 Contains Supplementary Figures S1-S6.

934 **Additional file 2:** Table S1

935 Complete differential expression results between AAA and controls.

936 **Additional file 3:** Table S2

937 GO functional enrichment analysis results between AAA and controls (including genes affected  
938 by ischemic time).

939 **Additional file 4:** Table S3

940 KEGG functional enrichment analysis results between AAA and controls (including genes  
941 affected by ischemic time).

942 **Additional file 5:** Table S4

943 Differential expressed genes by ischemic time in GTEx samples.

944 **Additional file 6:** Table S5

945 GO functional enrichment analysis results between AAA and controls (excluding genes affected  
946 by ischemic time).

947 **Additional file 7:** Table S6

948 KEGG functional enrichment analysis results between AAA and controls (excluding genes  
949 affected by ischemic time).

950     **Additional file 8:** Table S7














951     Results of the alternative splicing study between AAA and controls.

952     **Additional file 9:** Table S8

953     Complete differential expression results between AAA of different diameter.


954     **Additional file 10:** Table S9

955     Correlation analysis between biological and technical covariates.







A)



B)




C)







A)




Alternative 5' Splice Site Alternative First Exon  
Mutually Exclusive Exons Skipping Exon

C)

B)



A)



B)

